NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
10
HRTS Quote, Financials, Valuation and Earnings
Last price:
$29.38
Seasonality move
:
12.99%
Day range:
$28.90 - $29.52
52-week range:
$28.81 - $36.03
Dividend yield:
0.49%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
10K
Avg. volume:
16K
1-year change:
0.38%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$29.15 | -- | -- | -- | $0.47 | 0.49% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.24 | -- | -- | -- | $0.10 | 0.75% | -- |
|
CANC
Tema Oncology ETF
|
$24.45 | -- | -- | -- | $0.96 | 2.98% | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
$25.03 | -- | -- | -- | $0.11 | 0.45% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.03 | -- | -- | -- | $0.00 | 0% | -- |
|
MEDI
Harbor Health Care ETF
|
$25.03 | -- | -- | -- | $0.13 | 0.54% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.605 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 1.009 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 1.201 | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | 1.297 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.788 | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | 1.452 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
FMED
Fidelity Disruptive Medicine ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
MEDI
Harbor Health Care ETF
|
-- | -- | -- | -- | -- | -- |
Tema GLP-1, Obesity & Cardiometabolic ETF vs. Competitors
-
Which has Higher Returns HRTS or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HRTS or AGNG More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.927%.
-
Which is a Better Dividend Stock HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Global X Aging Population ETF offers a yield of 0.75% to investors and pays a quarterly dividend of $0.10 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HRTS or CANC?
Tema Oncology ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Tema Oncology ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is HRTS or CANC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Tema Oncology ETF offers a yield of 2.98% to investors and pays a quarterly dividend of $0.96 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns HRTS or FMED?
Fidelity Disruptive Medicine ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Fidelity Disruptive Medicine ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- -
What do Analysts Say About HRTS or FMED?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity Disruptive Medicine ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Fidelity Disruptive Medicine ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Fidelity Disruptive Medicine ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 FMEDFidelity Disruptive Medicine ETF0 0 0 -
Is HRTS or FMED More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fidelity Disruptive Medicine ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or FMED?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Fidelity Disruptive Medicine ETF offers a yield of 0.45% to investors and pays a quarterly dividend of $0.11 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Fidelity Disruptive Medicine ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or FMED?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Fidelity Disruptive Medicine ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Fidelity Disruptive Medicine ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Fidelity Disruptive Medicine ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Fidelity Disruptive Medicine ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- FMEDFidelity Disruptive Medicine ETF-- -- -- --
-
Which has Higher Returns HRTS or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is HRTS or HTEC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.070, suggesting its more volatile than the S&P 500 by 6.985%.
-
Which is a Better Dividend Stock HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns HRTS or MEDI?
Harbor Health Care ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Harbor Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- MEDIHarbor Health Care ETF-- -- -- -
What do Analysts Say About HRTS or MEDI?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Harbor Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Harbor Health Care ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Harbor Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 MEDIHarbor Health Care ETF0 0 0 -
Is HRTS or MEDI More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harbor Health Care ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or MEDI?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Harbor Health Care ETF offers a yield of 0.54% to investors and pays a quarterly dividend of $0.13 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Harbor Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or MEDI?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Harbor Health Care ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Harbor Health Care ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Harbor Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Harbor Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- MEDIHarbor Health Care ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
